Testing a JAK inhibitor to help RA joint erosion heal
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have rheumatoid arthritis that meets the 2010 ACR/EULAR diagnosis rules
- Have been taking methotrexate for at least 12 weeks
- Have active RA symptoms based on DAS28-CRP score above 3.2
- Use only methotrexate and (if applicable) hydroxychloroquine as your other RA medicines—no other past “disease-modifying” drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if baricitinib, a medication for rheumatoid arthritis, can improve blood clotting issues that some patients with active RA face. It is for adults whose RA is not well-controlled by standard treatments.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This trial compares a newer type of medication called JAK inhibitors to standard treatments for rheumatoid arthritis (RA). It aims to see which works better for managing symptoms.
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
This trial tests a new medicine called CIT-013 for people with rheumatoid arthritis. It aims to see if CIT-013 can help reduce joint swelling and pain when added to your current treatment.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.